Ptaeroxylon obliquum leaf extracts, fractions and isolated compounds as potential inhibitors of 15-lipoxygenase and lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells

dc.contributor.authorRamadwa, Thanyani Emelton
dc.contributor.authorDzoyem, Jean Paul
dc.contributor.authorAdebayo, S.A.
dc.contributor.authorEloff, Jacobus Nicolaas
dc.date.accessioned2023-07-11T11:32:52Z
dc.date.available2023-07-11T11:32:52Z
dc.date.issued2022-07
dc.description.abstractPtaeroxylon obliquum is used traditionally to treat inflammatory diseases and related symptoms such as arthritis, rheumatism, fever and headache. The aim of the study was to determine the anti-inflammatory activities of the crude extracts, fractions and isolated compounds from P. obliquum leaves. Nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages and soybean 15-lipoxygenase (15-LOX) inhibitory assays were used to evaluate the anti-inflammatory activity. The acetone crude extracts and fractions had weak 15-LOX inhibitory activity and also had some toxicity against the RAW 264.7 macrophage cells. The three isolated compounds, obliquumol, lupeol and β-amyrin mixture, and eranthin had good 15-LOX inhibitory activity with IC50 values ranging from 7.4 to 13.9 µg/mL which was in the same order as the positive control quercetin (2.1 µg/mL). The high percentage inhibition of NO production by the crude extracts, fractions and isolated compounds appeared to be due to the toxicity to the macrophage cells. Eranthin had the most promising activity with 71.1% inhibition and 89.1% cell viability at a 0.5 µg/mL concentration. The 15-LOX inhibitory activity of obliquumol, lupeol and β-amyrin mixture and eranthin may explain the traditional uses of P. obliquum to treat various inflammatory diseases even though the possibility that the anti-inflammatory activity might still be exerted through other inflammatory mechanisms.en_US
dc.description.departmentParaclinical Sciencesen_US
dc.description.librarianhj2023en_US
dc.description.sponsorshipThe National Research Foundation (NRF) and the University of Pretoria.en_US
dc.description.urihttp://www.elsevier.com/locate/sajben_US
dc.identifier.citationRamadwa, T.E., Dzoyem, J.P., Adebayo, S.A. & Eloff, J.N. 2022, 'Ptaeroxylon obliquum leaf extracts, fractions and isolated compounds as potential inhibitors of 15-lipoxygenase and lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells', South African Journal of Botany, vol. 147, pp. 192-196, doi : 10.1016/j.sajb.2022.01.014.en_US
dc.identifier.issn0254-6299 (print)
dc.identifier.issn1727-9321 (online)
dc.identifier.other10.1016/j.sajb.2022.01.014
dc.identifier.urihttp://hdl.handle.net/2263/91334
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2022 Published by Elsevier B.V. on behalf of SAAB. Notice : this is the author’s version of a work that was accepted for publication in South African Journal of Botany. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in South African Journal of Botany, vol. 147, pp. 192-196, 2022, doi : 10.1016/j.sajb.2022.01.014.en_US
dc.subjectPtaeroxylon obliquumen_US
dc.subjectInflammationen_US
dc.subjectNitric oxideen_US
dc.subjectLipoxygenaseen_US
dc.subjectObliquumolen_US
dc.subjectEranthinen_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titlePtaeroxylon obliquum leaf extracts, fractions and isolated compounds as potential inhibitors of 15-lipoxygenase and lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cellsen_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ramadwa_Ptaeroxylon_2022.pdf
Size:
289.76 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: